Eli Lilly requests for EUA approval from FDA for COVID-19 antibody
Category: #health  | By Nikita Chaurasia  | Date: 2020-10-09 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly requests for EUA approval from FDA for COVID-19 antibody

Eli Lilly and Company, the American pharmaceutical giant, has reportedly applied for emergency use authorization (EUA) for its potential COVID-19 antibody from the Food & Drug Administration (FDA). Sources with knowledge of the matter stated that the company has applied for EUA based on its previous study results and new information.

For those unfamiliar, Eli Lilly has developed a monoclonal antibody combination therapy called LY-CoV555 in order to treat the patients suffering from mild-to-moderate COVID-19. The company claims that its experimental antibody can help in reducing the virus level in the body as well as the overall hospitalization rates.

According to credible sources, the Phase 2 trials of the potential antibody comprised of around 112 people while up to 156 individuals were given a placebo. In this context, Eli Lilly specified that the patients who received the antibody therapy witnessed a significant decline in their virus levels after three to seven days.

Moreover, the company stated that over 0.9% of the patients on treatment went to emergency room or were hospitalized. Around 5.8% of the patients on placebo were apparently hospitalized as well.

Professor of pharmacoepidemiology at London School of Hygiene & Tropical Medicine, Stephen Evans was reported saying that although the data of phase 2 trials is encouraging, the experimental drug is still at preliminary stage. He further mentioned that the evidence derived from LY-CoV555 trials is not effective and needs to be studied more.

It is to be noted that Eli Lilly plans to produce over 1 million doses of its potential vaccine after receiving FDA authorization for its emergency use against the virus.

In other news, the FDA has reportedly informed the pharmaceutical companies to provide two months of safety data before authorizing the emergency use of their respective vaccines.

Source credits-

https://edition.cnn.com/2020/10/07/health/eli-lilly-antibody-therapy-results-eua/index.html

https://www.news18.com/news/world/u-s-fda-safety-guidelines-likely-to-push-covid-19-vaccine-authorization-past-election-2939275.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

PM Liz Truss to launch comprehensive review of UK’s visa policy

PM Liz Truss to launch comprehensive review of UK’s visa policy

By Nikita Chaurasia

Newly appointed Prime Minister Liz Truss is considering doing a complete review of Britain's visa system, as the nation struggles with severe labor shortages in vital industries. Business leaders across the UK have reportedly praised the decision...

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...

Flipkart introduces new tech and design upgrades ahead of holiday season

Flipkart introduces new tech and design upgrades ahead of holiday season

By Nikita Chaurasia

Flipkart, India's indigenous online marketplace, is reportedly offering customers an improved shopping experience on its widely popular app. To better serve various client groups that are exploring e-commerce during the holiday season, Flipkar...